Press release
Incyte Strengthens Research & Development Efforts Appointing Pablo J. Cagnoni, M.D. to New Leadership Role
Dr. Cagnoni joins Incyte’s Executive Team as President and Head of Research & Development WILMINGTON, Del.--(BUSINESS WIRE)-- Incyte (Nasdaq:INCY) today
About this update from Incyte Corporation
[{"type":"text","content":"\nDr. Cagnoni joins Incyte’s Executive Team as President and Head of Research & Development\n\n\n WILMINGTON, Del.--(BUSINESS WIRE)--\nIncyte (Nasdaq:INCY) today announced the creation of a new leadership role, appointing Pablo J. Cagnoni, M.D. President and Head of Research & Development (R&D) effective June 5, 2023. In this role and as a member of the Executive Team, Dr. Cagnoni will lead Incyte’s R&D efforts across its portfolio of programs in Oncology, Hematology and Inflammation and Autoimmunity including Dermatology.\n\n\n“This newly created role integrates chemistry, biology and development with the goal of maximizing the impact of our portfolio and accelerating our innovative pipeline,” said Hervé Hoppenot, Chief Executive Officer, Incyte. “Based on Pablo’s deep industry experience in all stages of drug development across different therapeutic modalities, as well as his proven track record of leading development organizations, he will play a critical role in helping us deliver on our commitment to patients, clinicians, our employees and shareholders.”\n\n\nAs an oncologist and pharmaceutical executive, Dr. Cagnoni has advanced the development of breakthrough treatments throughout his career playing a key role in the development, approval and/or commercialization of more than 20 life-changing medicines.\n\n\n“Incyte has a strong foundation of bringing first-in-class treatments to patients and I am honored to join the organization,” said Dr. Cagnoni. “I look forward to working with the team to continue to deliver major advances across Oncology and Dermatology, and to fully realizing the potential of the broad and diverse pipeline to make a significant difference for patients.”\n\n\nPablo most recently served as Chief Executive Officer of Laronde, a company dedicated to the development of a new type of translatable ribonucleic acid (RNA), endless RNA (eRNA). Previously he was President and Chief Executive Officer of Rubius Therapeutics, a biopharmaceutical company focused on cellular therapies for the treatment of cancer and autoimmune diseases. Before joining Rubius he was Chief Executive Officer of Tizona Therapeutics, a privately held biotech company focused on developing immunotherapies for the treatment of cancer. He joined Tizona as the company’s first employee and grew the organization to support the filing of its fi...